# Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

> **NCT05215561** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Psoriasis Vulgaris
- Psoriatic Arthritis
- Pustular Psoriasis

## Interventions

- **OTHER:** Cosentyx

## Key facts

- **NCT ID:** NCT05215561
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-14
- **Primary completion:** 2024-09-28
- **Final completion:** 2024-09-28
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05215561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05215561, "Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05215561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*